Alendronate treatment alters bone tissues at multiple structural levels in healthy canine cortical bone

Claire Acevedo, Hrishikesh Bale, Bernd Gludovatz, Amy Wat, Simon Y. Tang, Mingyue Wang, Björn Busse, Elizabeth A. Zimmermann, Eric Schaible, Matthew R. Allen, David B. Burr, Robert O. Ritchie

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Bisphosphonates are widely used to treat osteoporosis, but have been associated with atypical femoral fractures (AFFs) in the long term, which raises a critical health problem for the aging population. Several clinical studies have suggested that the occurrence of AFFs may be related to the bisphosphonate-induced changes of bone turnover, but large discrepancies in the results of these studies indicate that the salient mechanisms responsible for any loss in fracture resistance are still unclear. Here the role of bisphosphonates is examined in terms of the potential deterioration in fracture resistance resulting from both intrinsic (plasticity) and extrinsic (shielding) toughening mechanisms, which operate over a wide range of length-scales. Specifically, we compare the mechanical properties of two groups of humeri from healthy beagles, one control group comprising eight females (oral doses of saline vehicle, 1. mL/kg/day, 3. years) and one treated group comprising nine females (oral doses of alendronate used to treat osteoporosis, 0.2. mg/kg/day, 3. years). Our data demonstrate treatment-specific reorganization of bone tissue identified at multiple length-scales mainly through advanced synchrotron x-ray experiments. We confirm that bisphosphonate treatments can increase non-enzymatic collagen cross-linking at molecular scales, which critically restricts plasticity associated with fibrillar sliding, and hence intrinsic toughening, at nanoscales. We also observe changes in the intracortical architecture of treated bone at microscales, with partial filling of the Haversian canals and reduction of osteon number. We hypothesize that the reduced plasticity associated with BP treatments may induce an increase in microcrack accumulation and growth under cyclic daily loadings, and potentially increase the susceptibility of cortical bone to atypical (fatigue-like) fractures.

Original languageEnglish (US)
Pages (from-to)352-363
Number of pages12
JournalBone
Volume81
DOIs
StatePublished - Dec 1 2015

Fingerprint

Alendronate
Diphosphonates
Canidae
Haversian System
Bone and Bones
Femoral Fractures
Osteoporosis
Stress Fractures
Synchrotrons
Bone Remodeling
Humerus
Collagen
X-Rays
Control Groups
Cortical Bone
Health
Growth
Population

Keywords

  • Anti-resorptives
  • Bisphosphonates
  • Fracture prevention
  • Fracture toughness
  • Osteoporosis

ASJC Scopus subject areas

  • Physiology
  • Endocrinology, Diabetes and Metabolism
  • Histology

Cite this

Acevedo, C., Bale, H., Gludovatz, B., Wat, A., Tang, S. Y., Wang, M., ... Ritchie, R. O. (2015). Alendronate treatment alters bone tissues at multiple structural levels in healthy canine cortical bone. Bone, 81, 352-363. https://doi.org/10.1016/j.bone.2015.08.002

Alendronate treatment alters bone tissues at multiple structural levels in healthy canine cortical bone. / Acevedo, Claire; Bale, Hrishikesh; Gludovatz, Bernd; Wat, Amy; Tang, Simon Y.; Wang, Mingyue; Busse, Björn; Zimmermann, Elizabeth A.; Schaible, Eric; Allen, Matthew R.; Burr, David B.; Ritchie, Robert O.

In: Bone, Vol. 81, 01.12.2015, p. 352-363.

Research output: Contribution to journalArticle

Acevedo, C, Bale, H, Gludovatz, B, Wat, A, Tang, SY, Wang, M, Busse, B, Zimmermann, EA, Schaible, E, Allen, MR, Burr, DB & Ritchie, RO 2015, 'Alendronate treatment alters bone tissues at multiple structural levels in healthy canine cortical bone', Bone, vol. 81, pp. 352-363. https://doi.org/10.1016/j.bone.2015.08.002
Acevedo, Claire ; Bale, Hrishikesh ; Gludovatz, Bernd ; Wat, Amy ; Tang, Simon Y. ; Wang, Mingyue ; Busse, Björn ; Zimmermann, Elizabeth A. ; Schaible, Eric ; Allen, Matthew R. ; Burr, David B. ; Ritchie, Robert O. / Alendronate treatment alters bone tissues at multiple structural levels in healthy canine cortical bone. In: Bone. 2015 ; Vol. 81. pp. 352-363.
@article{cea70280a4bb48449b95c80c26526319,
title = "Alendronate treatment alters bone tissues at multiple structural levels in healthy canine cortical bone",
abstract = "Bisphosphonates are widely used to treat osteoporosis, but have been associated with atypical femoral fractures (AFFs) in the long term, which raises a critical health problem for the aging population. Several clinical studies have suggested that the occurrence of AFFs may be related to the bisphosphonate-induced changes of bone turnover, but large discrepancies in the results of these studies indicate that the salient mechanisms responsible for any loss in fracture resistance are still unclear. Here the role of bisphosphonates is examined in terms of the potential deterioration in fracture resistance resulting from both intrinsic (plasticity) and extrinsic (shielding) toughening mechanisms, which operate over a wide range of length-scales. Specifically, we compare the mechanical properties of two groups of humeri from healthy beagles, one control group comprising eight females (oral doses of saline vehicle, 1. mL/kg/day, 3. years) and one treated group comprising nine females (oral doses of alendronate used to treat osteoporosis, 0.2. mg/kg/day, 3. years). Our data demonstrate treatment-specific reorganization of bone tissue identified at multiple length-scales mainly through advanced synchrotron x-ray experiments. We confirm that bisphosphonate treatments can increase non-enzymatic collagen cross-linking at molecular scales, which critically restricts plasticity associated with fibrillar sliding, and hence intrinsic toughening, at nanoscales. We also observe changes in the intracortical architecture of treated bone at microscales, with partial filling of the Haversian canals and reduction of osteon number. We hypothesize that the reduced plasticity associated with BP treatments may induce an increase in microcrack accumulation and growth under cyclic daily loadings, and potentially increase the susceptibility of cortical bone to atypical (fatigue-like) fractures.",
keywords = "Anti-resorptives, Bisphosphonates, Fracture prevention, Fracture toughness, Osteoporosis",
author = "Claire Acevedo and Hrishikesh Bale and Bernd Gludovatz and Amy Wat and Tang, {Simon Y.} and Mingyue Wang and Bj{\"o}rn Busse and Zimmermann, {Elizabeth A.} and Eric Schaible and Allen, {Matthew R.} and Burr, {David B.} and Ritchie, {Robert O.}",
year = "2015",
month = "12",
day = "1",
doi = "10.1016/j.bone.2015.08.002",
language = "English (US)",
volume = "81",
pages = "352--363",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Alendronate treatment alters bone tissues at multiple structural levels in healthy canine cortical bone

AU - Acevedo, Claire

AU - Bale, Hrishikesh

AU - Gludovatz, Bernd

AU - Wat, Amy

AU - Tang, Simon Y.

AU - Wang, Mingyue

AU - Busse, Björn

AU - Zimmermann, Elizabeth A.

AU - Schaible, Eric

AU - Allen, Matthew R.

AU - Burr, David B.

AU - Ritchie, Robert O.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Bisphosphonates are widely used to treat osteoporosis, but have been associated with atypical femoral fractures (AFFs) in the long term, which raises a critical health problem for the aging population. Several clinical studies have suggested that the occurrence of AFFs may be related to the bisphosphonate-induced changes of bone turnover, but large discrepancies in the results of these studies indicate that the salient mechanisms responsible for any loss in fracture resistance are still unclear. Here the role of bisphosphonates is examined in terms of the potential deterioration in fracture resistance resulting from both intrinsic (plasticity) and extrinsic (shielding) toughening mechanisms, which operate over a wide range of length-scales. Specifically, we compare the mechanical properties of two groups of humeri from healthy beagles, one control group comprising eight females (oral doses of saline vehicle, 1. mL/kg/day, 3. years) and one treated group comprising nine females (oral doses of alendronate used to treat osteoporosis, 0.2. mg/kg/day, 3. years). Our data demonstrate treatment-specific reorganization of bone tissue identified at multiple length-scales mainly through advanced synchrotron x-ray experiments. We confirm that bisphosphonate treatments can increase non-enzymatic collagen cross-linking at molecular scales, which critically restricts plasticity associated with fibrillar sliding, and hence intrinsic toughening, at nanoscales. We also observe changes in the intracortical architecture of treated bone at microscales, with partial filling of the Haversian canals and reduction of osteon number. We hypothesize that the reduced plasticity associated with BP treatments may induce an increase in microcrack accumulation and growth under cyclic daily loadings, and potentially increase the susceptibility of cortical bone to atypical (fatigue-like) fractures.

AB - Bisphosphonates are widely used to treat osteoporosis, but have been associated with atypical femoral fractures (AFFs) in the long term, which raises a critical health problem for the aging population. Several clinical studies have suggested that the occurrence of AFFs may be related to the bisphosphonate-induced changes of bone turnover, but large discrepancies in the results of these studies indicate that the salient mechanisms responsible for any loss in fracture resistance are still unclear. Here the role of bisphosphonates is examined in terms of the potential deterioration in fracture resistance resulting from both intrinsic (plasticity) and extrinsic (shielding) toughening mechanisms, which operate over a wide range of length-scales. Specifically, we compare the mechanical properties of two groups of humeri from healthy beagles, one control group comprising eight females (oral doses of saline vehicle, 1. mL/kg/day, 3. years) and one treated group comprising nine females (oral doses of alendronate used to treat osteoporosis, 0.2. mg/kg/day, 3. years). Our data demonstrate treatment-specific reorganization of bone tissue identified at multiple length-scales mainly through advanced synchrotron x-ray experiments. We confirm that bisphosphonate treatments can increase non-enzymatic collagen cross-linking at molecular scales, which critically restricts plasticity associated with fibrillar sliding, and hence intrinsic toughening, at nanoscales. We also observe changes in the intracortical architecture of treated bone at microscales, with partial filling of the Haversian canals and reduction of osteon number. We hypothesize that the reduced plasticity associated with BP treatments may induce an increase in microcrack accumulation and growth under cyclic daily loadings, and potentially increase the susceptibility of cortical bone to atypical (fatigue-like) fractures.

KW - Anti-resorptives

KW - Bisphosphonates

KW - Fracture prevention

KW - Fracture toughness

KW - Osteoporosis

UR - http://www.scopus.com/inward/record.url?scp=84939511766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939511766&partnerID=8YFLogxK

U2 - 10.1016/j.bone.2015.08.002

DO - 10.1016/j.bone.2015.08.002

M3 - Article

C2 - 26253333

AN - SCOPUS:84939511766

VL - 81

SP - 352

EP - 363

JO - Bone

JF - Bone

SN - 8756-3282

ER -